Page last updated: 2024-10-24

bupivacaine and Hallux Valgus

bupivacaine has been researched along with Hallux Valgus in 14 studies

Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.

Hallux Valgus: Lateral displacement of the great toe (HALLUX), producing deformity of the first METATARSOPHALANGEAL JOINT with callous, bursa, or BUNION formation over the bony prominence.

Research Excerpts

ExcerptRelevanceReference
"5% levobupivacaine (L) and 1% mepivacaine (M) for popliteal block for hallux valgus surgery."9.16[Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery]. ( Anglada, MT; Fábregas, N; Faulí, A; Gambús, P; Gomar, C; López, A; Pons, M; Sala, X, 2012)
"The use of a single dose of either levobupivacaine or ropivacaine to provide anesthesia for a popliteal approach to hallux valgus surgery is effective for controlling postoperative pain."9.14[Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery]. ( Anglada, MT; Fàbregas, N; Faulí, A; López, A; Pons, M; Pujol, E, 2010)
"The objective of this study was to review the use of liposomal bupivacaine as a multimodal pain management adjunct following hallux valgus surgery."7.80Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct. ( Huh, J; Parekh, SG, 2014)
"A randomised clinical study was conducted on ambulatory patients subjected to Hallux valgus surgery, assigned into two groups: BNP: peripheral nerve blockage: posterior tibial and the common peroneal with 80mg of lidocaine, 100mg of mepivacaine and 25mg of levobupivacaine."5.16[Comparison of the post-surgical analgesic effectiveness of tibial (at internal malleolus level) and common peroneal nerve block with infiltration of the surgical wound in Outpatient Surgery of the hallux valgus]. ( Martín, MA; Ollé, G; Pellejero, JA; Pou, N; Torruella, R; Yuste, M, 2012)
"5% levobupivacaine (L) and 1% mepivacaine (M) for popliteal block for hallux valgus surgery."5.16[Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery]. ( Anglada, MT; Fábregas, N; Faulí, A; Gambús, P; Gomar, C; López, A; Pons, M; Sala, X, 2012)
"The use of a single dose of either levobupivacaine or ropivacaine to provide anesthesia for a popliteal approach to hallux valgus surgery is effective for controlling postoperative pain."5.14[Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery]. ( Anglada, MT; Fàbregas, N; Faulí, A; López, A; Pons, M; Pujol, E, 2010)
"To compare intraoperative and postoperative clinical properties of levobupivacaine and ropivacaine for sciatic nerve block, 50 ASA physical status I and II patients undergoing hallux valgus repair received a femoral nerve block with 15 mL of 2% mepivacaine."5.10A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block. ( Borghi, B; Casati, A; Cerchierini, E; Fanelli, G; Grispigni, C; Santorsola, R; Sassoli, V; Torri, G, 2002)
"The objective of this study was to review the use of liposomal bupivacaine as a multimodal pain management adjunct following hallux valgus surgery."3.80Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct. ( Huh, J; Parekh, SG, 2014)
"The surgical treatment of hallux valgus deformity is connected with significant postoperative pain."2.80[Preemptive local anesthetic infiltration in hallux valgus one-day surgery]. ( Gądek, A; Liszka, H, 2015)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19901 (7.14)18.7374
1990's0 (0.00)18.2507
2000's6 (42.86)29.6817
2010's7 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Robbins, J1
Green, CL1
Parekh, SG2
Huh, J1
Gądek, A1
Liszka, H1
Taboada, M2
Rodríguez, J2
Bermudez, M1
Valiño, C1
Ulloa, B1
Aneiros, F1
Gude, F1
Cortés, J1
Alvarez, J2
Atanassoff, PG1
Pujol, E1
Faulí, A2
Anglada, MT2
López, A2
Pons, M2
Fàbregas, N2
Golf, M1
Daniels, SE1
Onel, E1
Martín, MA1
Ollé, G1
Pellejero, JA1
Torruella, R1
Yuste, M1
Pou, N1
Gomar, C1
Sala, X1
Gambús, P1
Sinardi, D1
Marino, A1
Chillemi, S1
Siliotti, R1
Mondello, E1
Carceller, J1
Lagunilla, J1
Bárcena, M1
Palmisani, S1
Arcioni, R1
Di Benedetto, P2
De Blasi, RA1
Mercieri, M1
Ronconi, P1
Casati, A2
Borghi, B1
Fanelli, G1
Cerchierini, E2
Santorsola, R2
Sassoli, V1
Grispigni, C2
Torri, G2
Chelly, JE1
Nobili, F1
Porter, KM1
Davies, J1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Liposomal Bupivicaine on Post-Operative Pain in Orthopaedic Trauma Surgery: A Double-Blind Prospective Randomized Control Trial[NCT02480621]Phase 384 participants (Actual)Interventional2014-12-31Completed
The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions[NCT01226927]45 participants (Actual)Interventional2009-04-30Completed
Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride[NCT03270514]Phase 360 participants (Actual)Interventional2018-11-15Completed
Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794]Phase 325 participants (Actual)Interventional2017-10-25Terminated (stopped due to Interim Analysis showed no significance)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Administration of SKY0402 for Prolonged Postoperative Analgesia in Subjects Undergoing First Metatarsal Osteotomy (B[NCT00890682]Phase 3193 participants (Actual)Interventional2009-04-30Completed
Prospective Randomized Trial of Penile Nerve Block With Liposomal Bupivacaine for Hypospadias Repair vs Standard Penile Block With Bupivacaine[NCT04479371]Phase 10 participants (Actual)Interventional2021-07-31Withdrawn (stopped due to Limited funding and resources to complete FDA requirements for enrollment)
The Use of Liposomal Bupivacaine for Pain Control Following Mastectomy and Breast Reconstruction[NCT03722927]Phase 43 participants (Actual)Interventional2018-06-14Completed
A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy[NCT02352922]Phase 464 participants (Actual)Interventional2015-07-31Completed
[NCT00523289]Phase 448 participants (Anticipated)Interventional2007-10-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Pain Levels on a Visual Analog Scale ( VAS)

A Visual Analog Scale (VAS) ranging from 0 to 10 in increments of 1 was used to both qualitatively and quantitatively assess the level and severity of pain during the time points ranging from the immediate post-operative period through 72 hours post-operative. Each number on the scale is accompanied by a visual facial expression that indicates the level of pain, discomfort, and distress appropriate to the number on the scale. The more severe the level of pain, the higher the corresponding number and more distressing the accompanying facial expression. A VAS score of 0 indicates no active pain level and is accompanied by a pleasantly smiling face whereas a VAS score of 10 indicates the most severe active pain level and is accompanied by a visibly-distraught face that is frowning, grimacing, and sweating. The combination of facial expressions and numbers is supposed to provide a language-independent, validated means of assessing pain levels. (NCT02480621)
Timeframe: Immediate post-operative period until 72 hours post-operatively

,
Interventionunits on a scale (Mean)
4 Hours Post-operativePost-operative Day 1Post-operative Day 2Post-operative Day 3
Control7.057.496.645.72
Liposomal Bupivacaine With Bupivacaine4.036.605.224.08

Hospital Readmission

Readmission to hospital will be noted (NCT03270514)
Timeframe: From end of surgery assessed up to 30 days post-operatively

InterventionParticipants (Count of Participants)
Exparel Injectable Product3
Bupivacaine Hydrochloride3

Mortality

Mortality will be noted at specific timepoints (NCT03270514)
Timeframe: From end of surgery assessed up to 30 days post-operatively

InterventionParticipants (Count of Participants)
Exparel Injectable Product0
Bupivacaine Hydrochloride1

Non-invasive Ventilation (NIV) Requirement

Episodes of NIV such as upper airway masks or similar devices will be quantified (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively or until hospital discharge

InterventionParticipants (Count of Participants)
Exparel Injectable Product6
Bupivacaine Hydrochloride5

Patient Satisfaction

Patient will give an assessment regarding pain management on a scale of 0 - 10 with 0 indicating the lowest satisfaction with pain management and 10 indicating the highest satisfaction with pain management (NCT03270514)
Timeframe: Given at the time of discharge up to 30 days post-operatively

Interventionscore on a scale (Median)
Exparel Injectable Product10
Bupivacaine Hydrochloride10

Patient Time to Mobilization

The time it takes until patient ambulates will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of mobilization up to 72 hours or discharge, *assessed up to 120 hours*

Interventionhours (Median)
Exparel Injectable Product42
Bupivacaine Hydrochloride45

Patient Time to Oral Intake

The time it takes until the patient is able to/medically cleared to consume food or liquid will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of oral intake up to 72 hours post-operatively or until hospital discharge

Interventionhours (Median)
Exparel Injectable Product7
Bupivacaine Hydrochloride5.6

Patient Time to Out of Bed to Chair

The time it takes until the patient advances from bedrest to out of bed (OOB) to chair will be measured (NCT03270514)
Timeframe: From time of end of surgery to time of mobilization up to 72 hours post-operatively

Interventionhours (Median)
Exparel Injectable Product16
Bupivacaine Hydrochloride16

Post-operative Nausea and Vomiting

Whether a patient experiences at least one episode of nausea and emesis will be measured (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively

InterventionParticipants (Count of Participants)
Exparel Injectable Product3
Bupivacaine Hydrochloride9

Re-intubation

Instances of re-intubation will be recorded (NCT03270514)
Timeframe: From time of end of surgery to patient discharge up to one week

InterventionParticipants (Count of Participants)
Exparel Injectable Product3
Bupivacaine Hydrochloride3

Time to Extubation

The time it takes until the patient is extubated post-operatively will be measured (NCT03270514)
Timeframe: From the end of surgery until the patient is extubated up to 72 hours post-operatively

Interventionhours (Median)
Exparel Injectable Product3.85
Bupivacaine Hydrochloride3.47

Use of Incentive Spirometry

Frequency of incentive spirometry will be measured (NCT03270514)
Timeframe: From time of end of surgery to 72 hours post-operatively

InterventionParticipants (Count of Participants)
Exparel Injectable Product29
Bupivacaine Hydrochloride31

Length of Hospital and ICU Stay

Length of both hospital and ICU stay will be measured (NCT03270514)
Timeframe: From date of surgery assessed up to 30 day post-operatively

,
Interventiondays (Median)
Length of ICU stayLength of postoperative hospital stay
Bupivacaine Hydrochloride1.716
Exparel Injectable Product1.517

Post-operative Pain Intensity

Postoperative pain scores evaluated by numeric rating scale or (NRS) where 0- no pain and 10- worst pain, at rest and at movement (NCT03270514)
Timeframe: NRS scores will be evaluated every 4 hours until 24 hours post-operatively, every 8 hours until 48 hours post-operatively, and every 12 hours for 72 hours post-operatively

,
Interventionscore on a scale (Mean)
4hrs. at rest4hrs. with movement8hrs. at rest8hrs. with movement12hrs. at rest12hrs. with movement16hrs. at rest16hrs. with movement20hrs. at rest20hrs. with movement24hrs. at rest24hrs. with movement32hrs. at rest32hrs. with movement40hrs. at rest40hrs. with movement48hrs. at rest48hrs. with movement60hrs. at rest60hrs. with movement72hrs. at rest72hrs. with movement
Bupivacaine Hydrochloride5.036.644.9966.64.9626.564.9286.524.8946.484.866.444.7926.324.7246.244.6566.164.5546.044.4525.92
Exparel Injectable Product4.74825.754.72625.744.70425.734.68225.724.66025.714.63825.74.59425.684.52825.664.46225.644.37425.614.28625.58

Serum Cortisol Levels

Stress response suppression as a result of treatment will be evaluated by comparing hormone levels between the groups. Serum cortisol levels will be taken to measure this. (NCT03270514)
Timeframe: Measured 8, 48, and 72 hours post-operatively

,
Interventionµg/dL (Median)
8 hours postoperatively48 hours postoperatively72 hours postoperatively
Bupivacaine Hydrochloride36.51917
Exparel Injectable Product301516

Total Narcotic Consumption

All narcotics administered in the first 0-8, 8-24, 24-48, and 48-72 hours and the total narcotics administered in the 0-72 hours postoperative period(PCA narcotics, nurse-administered IV narcotics, and oral narcotics). All narcotics will be converted to total IV morphine equivalent for comparison between two groups. (NCT03270514)
Timeframe: 0-72 hours post-operative period

,
Interventionoral morphine equivalents in mg (Median)
0-8 hours8-24 hours24-48 hours48-72 hours0-72 hours
Bupivacaine Hydrochloride1034.54526.5105
Exparel Injectable Product15454515139

AM-PAC Score to Measure Patients Fitness for Discharge

AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1

Interventionscore on scale (Mean)
Bupivicaine23
Bupivicaine + Exparel23

Opioid Consumption During the First 48 Hours After TKA Surgery

Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery

Interventionmilligram (Mean)
Bupivicaine90
Bupivicaine + Exparel76

Pain Scores During 48 Hrs Postoperatively

Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively

Interventionscore on scale (Mean)
Bupivicaine4
Bupivicaine + Exparel4

Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores

"The AUC of the NRS-R pain intensity scores from time 0 through 24 hours~The subject was to rest for at least 5 minutes before responding to the following question, On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?" (NCT00890682)
Timeframe: 0-24 hours

InterventionUnits on a scale*hours (Geometric Mean)
SKY0402124
Placebo146

Frequency of Postoperative Opioid Related Adverse Effects

Frequency of postoperative opioid related adverse effects within the first week of surgery will be recorded. This includes nausea, vomiting, pruritus, allergy, respiratory depression. (NCT03722927)
Timeframe: Postoperatively, 1 week

InterventionParticipants (Count of Participants)
Bupivacaine Group0
Liposomal Bupivacaine Group0

Length of Stay for Hospitalization

The length of stay for hospitalization after mastectomy and breast reconstruction will be recorded. (NCT03722927)
Timeframe: up to 47 Hours

Interventiondays (Mean)
Bupivacaine Group1
Liposomal Bupivacaine Group1

Number of Morphine Doses Across All Subjects

This will be measured by the number of doses within the first month postoperatively and recorded on pain medication daily diary kept by subject. (NCT03722927)
Timeframe: 1 Month

InterventionNumber of morphine doses (Number)
Bupivacaine Group0
Liposomal Bupivacaine Group20

Readmission Rates to the Hospital

Readmission rates to the hospital within 2 months after mastectomy and breast reconstruction will be recorded (NCT03722927)
Timeframe: Month 2

InterventionParticipants (Count of Participants)
Bupivacaine Group0
Liposomal Bupivacaine Group0

Mean Visual Analog Scores

This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes. (NCT03722927)
Timeframe: 48 hours

Interventionscore on a scale (Mean)
12 hours
Bupivacaine Group4

Mean Visual Analog Scores

This will be measured every 12 hours for the first 48 hours postoperatively by the level of breast pain associated with arm movements while eating on a scale of 0-10 with higher scores denoting worse outcomes. (NCT03722927)
Timeframe: 48 hours

Interventionscore on a scale (Mean)
12 hours24 hours36 hours48 hours
Liposomal Bupivacaine Group3.543.52

NRS Pain Score at 16 Hours

Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 16 hours post-op

Interventionscore on a scale (Mean)
Liposomal Bupivacaine3.1
Bupivacaine HCl3.97

NRS Pain Score at 2 Hours

numeric rating scale (0-10), mean and SD, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 2 hours post-op

Interventionunits on a scale (Mean)
Liposomal Bupivacaine2.53
Bupivacaine HCl2.74

NRS Pain Score at 4 Hours

Pain scale measured from 0-10, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 4 hours post-op

InterventionScore on a scale (Mean)
Liposomal Bupivacaine3.87
Bupivacaine HCl3

NRS Pain Score at 8 Hours

Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 8 hours post-op

InterventionScore on a scale (Mean)
Liposomal Bupivacaine3.77
Bupivacaine HCl3.67

NRS Pain Score Post-op Day 14

Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: Post-Operative Day 14

Interventionscore on a scale (Mean)
Liposomal Bupivacaine1.64
Bupivacaine HCl2.07

NRS Pain Score Post-op Day 2

Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 2 days post-op

Interventionscore on a scale (Mean)
Liposomal Bupivacaine3.34
Bupivacaine HCl4.17

NRS Pain Score Post-op Day 3

Pain scale, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 3 days post-op

Interventionscore on a scale (Mean)
Liposomal Bupivacaine2.79
Bupivacaine HCl4.07

Numerical Rating Scale (NRS) Post-operative Pain Score on Post-Operative Day 1 (POD1).

Numerical Rating Scale (0-10) post-operative pain score on POD1, where 0 = no pain and 10 = worst pain imaginable (NCT02352922)
Timeframe: 24 hours

Interventionunits on a scale (Mean)
Liposomal Bupivacaine4.17
Bupivacaine HCl4.97

Quality of Life as Measured by the Brief Pain Inventory (BPI)

at time of post-op visit The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 14

Interventionscore on a scale (Mean)
Liposomal Bupivacaine1.74
Bupivacaine HCl1.65

Quality of Life as Measured by the Brief Pain Inventory (BPI)

The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 2

Interventionscore on a scale (Mean)
Liposomal Bupivacaine4.09
Bupivacaine HCl4.31

Quality of Life as Measured by the Brief Pain Inventory (BPI)

The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes (NCT02352922)
Timeframe: Post-Operative Day 3

Interventionscore on a scale (Mean)
Liposomal Bupivacaine3.36
Bupivacaine HCl3.94

Total Opioid Use at Post-op Day 14

Total use of home opioids by pill count/ oral morphine equivalents (NCT02352922)
Timeframe: Post-Operative Day 14

Interventionmg (oral morphine equivalents) (Mean)
Liposomal Bupivacaine360
Bupivacaine HCl443

Total Opioid Use End of Post-op Day 3

Total use of home opioids by pill count/ oral morphine equivalents (NCT02352922)
Timeframe: 72 hrs post-op

Interventionmg (oral morphine equivalents) (Mean)
Liposomal Bupivacaine320
Bupivacaine HCl344

Total Opioid Use Prior to Hospital Discharge

Oral morphine equivalent of opioid use while in the hospital (NCT02352922)
Timeframe: 24 hours

Interventionmg (oral morphine equivalents) (Mean)
Liposomal Bupivacaine216
Bupivacaine HCl266

Number of Participants With Adverse Events

(NCT02352922)
Timeframe: Post-Operative Day 14

,
InterventionParticipants (Count of Participants)
Gas distension/bloatedConstipationNauseaHeadacheSore throat/coughDizziness
Bupivacaine HCl926733
Liposomal Bupivacaine554211

Trials

12 trials available for bupivacaine and Hallux Valgus

ArticleYear
[Preemptive local anesthetic infiltration in hallux valgus one-day surgery].
    Przeglad lekarski, 2015, Volume: 72, Issue:1

    Topics: Acetaminophen; Ambulatory Surgical Procedures; Anesthesia, Local; Anesthetics, Local; Bupivacaine; H

2015
A "new" automated bolus technique for continuous popliteal block: a prospective, randomized comparison with a continuous infusion technique.
    Anesthesia and analgesia, 2008, Volume: 107, Issue:4

    Topics: Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Hallux Valgus; Humans; Infusion Pumps;

2008
[Ultrasound-guided single dose injection of 0.5% levobupivacaine or 0.5% ropivacaine for a popliteal fossa nerve block in unilateral hallux valgus surgery].
    Revista espanola de anestesiologia y reanimacion, 2010, Volume: 57, Issue:5

    Topics: Aged; Amides; Analgesics; Anesthetics, Local; Bupivacaine; Female; Hallux Valgus; Humans; Injections

2010
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy.
    Advances in therapy, 2011, Volume: 28, Issue:9

    Topics: Adult; Aged; Anesthetics, Local; Area Under Curve; Bupivacaine; Delayed-Action Preparations; Double-

2011
[Comparison of the post-surgical analgesic effectiveness of tibial (at internal malleolus level) and common peroneal nerve block with infiltration of the surgical wound in Outpatient Surgery of the hallux valgus].
    Revista espanola de anestesiologia y reanimacion, 2012, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Aged; Ambulatory Surgical Procedures; Analgesics; Ankle; Bupivacaine; Electric St

2012
[Comparison of 3 combinations of 0.5% levobupivacaine and 1% mepivacaine in popliteal sciatic block in hallux valgus outpatient surgery].
    Revista espanola de anestesiologia y reanimacion, 2012, Volume: 59, Issue:10

    Topics: Aged; Ambulatory Surgical Procedures; Anesthetics, Combined; Anesthetics, Local; Bupivacaine; Double

2012
Sciatic nerve block with lateral popliteal approach for hallux vagus correction. Comparison between 0.5% bupivacaine and 0.75% ropivacaine.
    Minerva anestesiologica, 2004, Volume: 70, Issue:9

    Topics: Adult; Aged; Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Hallux Valgus; Hu

2004
Stimulating popliteal catheters for postoperative analgesia after hallux valgus repair.
    Anesthesia and analgesia, 2006, Volume: 102, Issue:1

    Topics: Aged; Bupivacaine; Catheterization; Female; Hallux Valgus; Humans; Levobupivacaine; Male; Middle Age

2006
Ropivacaine and levobupivacaine for bilateral selective ankle block in patients undergoing hallux valgus repair.
    Acta anaesthesiologica Scandinavica, 2008, Volume: 52, Issue:6

    Topics: Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Elective Surgical Procedures; Female;

2008
A double-blinded, randomized comparison of either 0.5% levobupivacaine or 0.5% ropivacaine for sciatic nerve block.
    Anesthesia and analgesia, 2002, Volume: 94, Issue:4

    Topics: Adult; Aged; Amides; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Femoral Nerve; Ha

2002
Clinical properties of levobupivacaine or racemic bupivacaine for sciatic nerve block.
    Journal of clinical anesthesia, 2002, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Aged; Anesthetics, Local; Bupivacaine; Double-Blind Method; Female; Femoral Nerve

2002
The control of pain after Keller's procedure--a controlled double blind prospective trial with local anaesthetic and placebo.
    Annals of the Royal College of Surgeons of England, 1985, Volume: 67, Issue:5

    Topics: Anesthesia, Local; Arthroplasty; Bupivacaine; Clinical Trials as Topic; Double-Blind Method; Hallux

1985

Other Studies

2 other studies available for bupivacaine and Hallux Valgus

ArticleYear
Liposomal bupivacaine in forefoot surgery.
    Foot & ankle international, 2015, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Fem

2015
Liposomal bupivacaine in hallux valgus surgery: a multimodal pain management adjunct.
    Journal of surgical orthopaedic advances, 2014,Winter, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Bupivacaine; Female; Hallux Valgus; Humans; Male

2014